Hi SanFran. Good points.

I picked up on the China comments as well and it's an interesting strategy for a number of reasons not in the least of which is population and growth. It breaks the typical North American myopia of the NA and Europe focus.

Regarding Benzodiazepines he pointed out how the FDA is quite comfortable with the epigenetic platforms and Zenith for trial approvals because of the lack of risk and I would speculate that as every drug development company jumps on the epigenetic bandwagon the approval process may become even more efficient (???).

Cheers

Toinv :)